Vida Strategic Partners President and CEO to Participate on Investor Relations Best Practices Panel at NIRI 2018
06 juin 2018 07h57 HE
|
Vida Strategic Partners, Inc.
SAN FRANCISCO, June 06, 2018 (GLOBE NEWSWIRE) -- Vida Strategic Partners, an advisory firm supporting the financial, operational and communications goals of life science and healthcare companies,...
San Francisco Suicide Prevention Partners With Punk Rockers to Save Lives
05 mars 2015 11h00 HE
|
Rock For Life
SAN FRANCISCO, CA--(Marketwired - Mar 5, 2015) - San Francisco Suicide Prevention (SFSP) announced today that they will once again partner with Global Affront, a San Francisco punk rock band, to...
Global Blood Therapeutics Announces First Cohort Dosed in Phase I/II Trial of GBT440 in Sickle Cell Disease
12 janv. 2015 07h35 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, CA--(Marketwired - Jan 12, 2015) - Global Blood Therapeutics (GBT), a biopharmaceutical company developing novel, small molecule therapeutics for the treatment of severe blood...
Willie L. Brown, Jr. Joins the Board of Directors of Global Blood Therapeutics
08 janv. 2015 07h35 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, CA--(Marketwired - Jan 8, 2015) - Global Blood Therapeutics (GBT), a biopharmaceutical company developing novel, small molecule therapeutics for the treatment of severe blood...
Global Blood Therapeutics Completes $48 Million Series B Financing
06 janv. 2015 07h35 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, CA--(Marketwired - Jan 6, 2015) - Global Blood Therapeutics (GBT), a biopharmaceutical company developing novel, small molecule therapeutics for the treatment of severe blood...
Global Blood Therapeutics to Present at Upcoming Investor Conferences
05 janv. 2015 07h35 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, CA--(Marketwired - Jan 5, 2015) - Global Blood Therapeutics (GBT), a biopharmaceutical company developing novel small molecule therapeutics for the treatment of severe blood...
Global Blood Therapeutics' GBT440 Demonstrates Ability to Positively Impact Fundamental Sickle Cell Disease (SCD) Processes in Studies Presented at 2014 American Society of Hematology (ASH) Conference
08 déc. 2014 10h00 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, CA--(Marketwired - Dec 8, 2014) - Global Blood Therapeutics (GBT), a biopharmaceutical company developing novel, orally available therapeutics for the treatment of severe...
Global Blood Therapeutics to Present New Data Highlighting Therapeutic Potential of GBT440 in Sickle Cell Disease (SCD) at 2014 American Society of Hematology (ASH) Conference
02 déc. 2014 07h35 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, CA--(Marketwired - Dec 2, 2014) - Global Blood Therapeutics (GBT), a biopharmaceutical company developing novel, orally available therapeutics for the treatment of severe...